Bruntwood, the family-owned commercial property company with over 100 office and scientific buildings across the UK, have agreed a 40,000 sq ft letting at Citylabs in Manchester to ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries.
Citylabs in Manchester is a new biomedical centre of excellence, located on the Oxford Road Corridor at the heart of Europe’s largest clinical and academic campus, formerly The Royal Eye Hospital. Bruntwood’s 94,000 sq ft development will retain the heritage listed frontage whilst building new space to the rear, which has been designed to attract bio health companies to develop new products and services within BREEAM Excellent office, laboratory and networking space.
Dr. Mario Rocci, President of ICON Development Solutions, said: “We are pleased to be expanding our early phase development services through the establishment of a Centre of Excellence for Translational Medicine in Citylabs. This expansion will enable ICON to increase the capacity of its Clinical Pharmacology Unit in Manchester as well as the scientific services that are essential in providing a world class offering.”
Chris Oglesby, Bruntwood’s Chief Executive, said: “We are delighted to welcome a global organisation like ICON to Citylabs and are looking forward to working in partnership with them and supporting their further growth plans in Manchester.”
Sir Richard Leese, leader of Manchester City Council, said: “Manchester has a proud tradition of cutting edge research and we recognise the knowledge-based economy as a crucial driver for growth and job creation. Citylabs stands at the heart of the Corridor, a nationally important concentration of knowledge-based assets, and the announcement that ICON will be establishing themselves here is hugely welcome.”
The Citylabs project received funding from the European Regional Development Fund and will open to the public in winter 2013. Other pre-lets at Citylabs include; The Central Manchester University Hospitals NHS Foundation Trust Charity’s main office, The Manchester College and TRUSTECH. The remaining space has been designed for clinical trials, biomedical laboratories, facilities for medtech companies and networking areas.
Mike Deegan, Central Manchester University Hospitals NHS Foundation Trust’s Chief Executive, said: “This exciting development supports our progress to be the leading hospital for research and patient care in England and Citylabs will strengthen our capability to support the development of new medicines and diagnostics for our patients. We are pleased that ICON, who are one of the market leaders in early phase trials, are expanding into Citylabs which will help our patients to get early access to leading edge new treatments.”
For further information please visit: www.citylabs.co.uk